- Report
- April 2025
- 200 Pages
Global
From €4112EUR$4,490USD£3,503GBP
- Report
- August 2022
- 100 Pages
Global
From €4121EUR$4,500USD£3,511GBP
- Report
- August 2023
- 113 Pages
Global
From €3500EUR$4,094USD£3,086GBP
- Report
- May 2025
- 50 Pages
Global
From €2427EUR$2,650USD£2,067GBP
Cilostazol is a cardiovascular drug used to treat intermittent claudication, a condition characterized by pain in the legs due to poor circulation. It works by inhibiting the enzyme phosphodiesterase-3, which increases the levels of cAMP in the body, leading to improved blood flow. Cilostazol is available in both generic and brand-name formulations. It is typically taken twice daily, with or without food.
Cilostazol is used in combination with lifestyle changes such as exercise and smoking cessation to improve symptoms of intermittent claudication. It is also used to reduce the risk of stroke and heart attack in patients with peripheral artery disease.
The cilostazol market is highly competitive, with several generic and brand-name formulations available. Companies in the market include Pfizer, Novartis, Teva Pharmaceuticals, Mylan, and Sun Pharmaceuticals. Show Less Read more